Copyright ©The Author(s) 2023.
World J Hepatol. Sep 27, 2023; 15(9): 1021-1032
Published online Sep 27, 2023. doi: 10.4254/wjh.v15.i9.1021
Figure 1
Figure 1 Management of tyrosine kinase inhibitor-induced hepatotoxicity according to European LeukemiaNet recommendations. aAdverse events may require specific treatment; bAlternatively, continue TKI for 1 wk with appropriate management of adverse event. If no resolution is achieved, withhold TKI until liver toxicity is grade < 2 and monitor weekly. TKI: Tyrosine kinase inhibitor.